Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Dec 16.
Published in final edited form as: J Urol. 2025 Oct 28;215(3):316–325. doi: 10.1097/JU.0000000000004832

Impact of renal mass biopsy on decision-making experience for clinical T1 renal masses

Kathryn H Gessner 1,2, Allison M Deal 2, Amir Feinberg 1, Shannon Myers 1, Katherine Poulos 3, Hillary Heiling 4, Sara Wobker 1,2,5, Pranav Akella 1, Marc A Bjurlin 1, Clayton Commander 6, Matthew I Milowsky 2,7, Matthew E Nielsen 1,2, Mathew Raynor 1, Angela B Smith 1,2, Eric Wallen 8, David C Johnson 1, William Y Kim 2,7, Hung-Jui Tan 1,2
PMCID: PMC12704500  NIHMSID: NIHMS2119628  PMID: 41151063

Abstract

Purpose:

Due to uncertainty on best management, a subset of patients with small renal masses suspicious for kidney cancer experience elevated decisional conflict. We hypothesize that pathologic information from renal mass biopsy may improve patient decision-making. In this study, we evaluate the impact of renal mass biopsy on decisional conflict for patients with clinical T1 renal masses.

Materials and Methods:

A comparative, non-randomized clinical trial was performed at a large tertiary cancer center. Patients with new clinical T1 renal masses were self-assigned to standard-of-care biopsy. We used difference-in-difference analyses to assess change in decisional conflict scale by receipt of renal mass biopsy.

Results:

Among 250 participants, 25% underwent biopsy during initial decision-making period prior to definitive intervention. Biopsy was more common for patients with masses >4 cm vs. 0–2 cm (PR 2.41, 95% CI 1.20–4.82, p=0.01), high nephrometry score vs. low (PR 2.13, 95% CI 1.13–4.01, p=0.02), and higher maximizer-minimizer score (PR 1.02, 95% CI 1.00–1.05, p=0.04). On adjusted difference-in-difference analysis, there was a small, non-significant reduction in decisional conflict for subjects undergoing biopsy vs. no biopsy (−2.78, 95% CI −7.18–1.45, p=0.20). Among subgroups, difference-in-difference by biopsy was large for total decisional conflict score in patients who did not see an outside urologist (−6.22) and patients reporting lower communication scores (−8.24).

Conclusions:

Though renal mass biopsy did not significantly decrease decisional conflict in all patients, biopsy reduced decisional conflict in certain patient subsets, demonstrating the importance of further investigating how to better support patients after renal mass diagnosis.

Keywords: Renal cell carcinoma, Shared decision-making, Core needle biopsy

Introduction

Kidney cancer incidence has more than doubled over the past decade to 81,800 projected cases in 2023.1 This growth has been driven by the incidental detection of small renal masses (SRMs), defined as masses ≤4 cm. Historically, the standard treatment for SRMs has been radical or partial nephrectomy, which demonstrates up to a 99% 3-year recurrence-free survival rate.2 However, up to 20–30% of SRMs are benign while less than 30% harbor aggressive disease.3,4 As such, thermal ablation and active surveillance (AS) have become effective and safe alternatives.4

With increased treatment options, decision-making has become more complicated, resulting in many patients experiencing decisional conflict.5 Decisional conflict refers to uncertainty or difficulty experienced when deciding on treatment and can lead to treatment regret and worse quality of life.6 Therefore, some have advocated for renal mass biopsy (RMB) to collect additional pathologic information and help guide decision-making.7 RMB is a percutaneous procedure that obtains core tissue samples using image-guidance with very low risk of morbidity.8 Histopathologic evaluation of RMB tissue can accurately distinguish malignancy from benign disease and offers fair performance in classifying prognostic factors like histologic subtype and nuclear grade.9 However, despite the safety and accuracy of RMB, only 8% of urologists routinely utilize RMBs for SRMs with debate on whether RMB alters clinical management.10 However, an underappreciated consideration may relate to decisional conflict. Specifically, information from an RMB may help patients process their diagnosis, leading to less decisional conflict and more effective decision-making.

In this context, we conducted a prospective, comparative, non-randomized clinical trial to evaluate the impact of RMB on decision-making (clinical arm) and the potential for RMB tissue obtained to be used for genomic assessment (translational arm, reported separately). In the clinical arm (reported herein), we hypothesized that patients undergoing RMB would have significantly reduced decisional conflict for management of their clinical stage T1 (cT1) renal mass (≤ 7 cm in diameter) compared to patients forgoing biopsy. By understanding the possible benefits to patient decision-making, we can better incorporate RMB into guidelines for cT1 renal masses.

Materials and Methods

Patient recruitment and enrollment

From October 2018–June 2022, we prospectively enrolled patients at our institution with newly diagnosed stage cT1 renal masses onto GRADE-SRM (Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses; NCT03819569; https://clinicaltrials.gov/ct2/show/NCT03819569). Inclusion criteria included patients ages 18–95, new renal mass ≤ 7 cm in diameter on cross-sectional radiologic study within 6 months of visit, and willingness to participate in study activities (including but not limited to collecting additional tissue for research purposes). Patients were excluded if staging information indicated locally advanced or metastatic disease, presence of transplant kidney or active evaluation for kidney transplant, previous RMB, history of metastatic cancer, incarcerated, non-English speaking, or unwilling or unable to complete informed consent.

Patients that met inclusion criteria and agreed to participation were consented and enrolled. Patients underwent standard-of-care counseling regarding their newly diagnosed cT1 renal mass and completed TP0 surveys within one week of initial encounter and TP1 surveys 4–8 weeks later. TP1 surveys were timed to be 1–2 week(s) post-RMB and prior to surgery or ablation if undergoing those procedures. Follow-up surveys and clinical information were collected as part of secondary aims. Patients were not compensated for participation.

Study protocol received approval from the institutional Cancer Center Protocol Review Committee as well as the institution’s Institutional Review Board (#18–1794). Study data were collected using REDCap electronic data capture tools.11

Exposure of Interest

Elective, standard-of-care RMB was the primary exposure of interest. UNC Interventional Radiology performed all RMBs according to standard-of-care protocols. Institutional standard is to utilize an 18-gauge needle for a core biopsy. Initial biopsy cores were sent for pathology with additional cores taken as tolerated for research tissue collection. Patients were counseled on pathology results typically within one week of biopsy.

Outcomes of Interest

The primary outcome was decisional conflict, as measured by the decisional conflict scale (DCS). DCS is a validated instrument that measures patient perceptions of uncertainty regarding the action to take, modifiable factors, and effective decision-making.12 DCS total score ranges 0–100 (higher scores indicate more decisional conflict) with scores <25 associated with implementing decisions. The DCS contains 5 subdomains: feeling uncertain, feeling uninformed, feeling unclear about values, feeling unsupported, and ineffective decision making.12 Consistent with other patient-reported outcomes (PROs), we considered a 0.5 SD difference to be clinically meaningful.13

Secondary outcomes included the above described DCS subdomains as well as cancer worry, generalized anxiety, and patient-centered communication (PCC). Participants completed a modified Brief Worry Scale, which measures the relationship between worry and a specific event, with higher scores indicating higher worry.14 Participants reported generalized anxiety through the Short Form PROMIS Anxiety scale, with higher scores indicating higher anxiety.15 PCC was measured using the Short-Form Patient-Centered Communication in Cancer Care Instrument16 which measures the patient perspective on communication in cancer care with higher scores indicating better perceived communication. Additional outcomes including RMB complications, histopathologic results, and treatment selection were recorded.

Covariates of Interest

Participants provided information on demographics, prior visit with an outside urologist, smoking history, and symptoms via survey. Patient age, evaluating urologist (deidentified as urologist 1–6), and additional objective information, including renal mass characteristics, were abstracted from the medical record. Tumor complexity was measured using R.E.N.A.L nephrometry scores (RENAL-NS), as determined by 1 urologist (KHG) blinded to RMB status, using cross-sectional imaging studies available at enrollment. Low RENAL-NS was defined as 4–6, while a high RENAL-NS was defined as 10–12. Validity and reliability of RENAL-NS have been previously described.17 The imaging reviewer classified masses as multifocal, cystic, or bilateral. After a protocol amendment in July 2019, described in detail previously,5 additional decision-making traits were evaluated at TP0 and TP1, including healthcare-seeking behavior, self-efficacy, and information-seeking behavior. Healthcare-seeking behavior was measured with the maximizer-minimizer scale, in which medical maximizers are defined as those who seek healthcare even for minor problems while minimizers prefer to avoid medical intervention unless necessary.18 We measured participant preferences for information using the information-seeking subscale of the Autonomy Preference Index (API) and self-efficacy using the General Self-Efficacy PROMIS measure.19,20

Statistical Methods

The study was designed to have 80% power to detect a 10-point difference in change in DCS over time (10 points decrease in RMB group, versus 0 in non-RMB) with at least 65 patients per group, assuming that the common standard deviation was 18.4 using a two-group t-test with 0.050 two-sided significance level. Assuming 30% of patients would choose to undergo RMB and to meet the translational endpoints, the trial planned to enroll 260 patients.

Continuous variables were summarized using means and standard deviation (SD). Categorical variables were summarized with frequencies and percentages. We used modified poisson regression to evaluate covariate association with RMB status and estimate prevalence ratios (PR); global Type III p-values are reported. In accordance with the planned primary analysis, we used a two-group t-test to compare the change in scores between groups for the primary objective. Additionally, difference-in-difference (DiD) analyses assessed change in total DCS between TP0 and TP1 by receipt of RMB. Specifically, a linear regression longitudinal model was used with generalized estimating equation methods to account for repeated measures within patients. DiD analysis accounts for background changes over time by comparison to a control group and incorporates regression modeling to account for other patient characteristics differing between control and exposure groups.21 The primary comparison is from the interaction term (RMB*timepoint) which tests if change over time is different between groups (difference-in-difference). Multivariable analyses (MVA) adjusted for potential confounders based on literature (age, BMI, urologist, mass type, Charlson Comorbidity Index) and study-specific results for p < 0.10 (education, RENAL-NS, Eastern Cooperative Oncology Group (ECOG) Performance Status, and smoking status). MVA did not adjust for mass diameter given correlation with RENAL-NS. For secondary outcomes, similar DiD analyses were performed.

We performed several post-hoc sensitivity analyses to assess the robustness of our findings. We first limited analysis to patients with clinical T1a (< 4 cm) masses and then to solid masses, given the difficulty of biopsy for cystic lesions. Third, we included only patients with higher TP0 DCS (DCS ≥25) scores. Lastly, we performed multiple post-hoc hypothesis-generating subgroup analyses to guide future studies. The subgroups were informed by prior research, clinical relevance, and stakeholder feedback from a patient panel formed for a follow-up study.5,22 Specifically, subgroups based on previous research included higher RENAL-NS scores, higher education levels, higher maximizer-minimizer scores, low self-efficacy, low information-seeking behavior (as measured by API), male sex, and lower PCC scores. Tumor size and type arose from clinical relevance while stakeholder feedback informed exploration of outside urologist and the above listed decision-making factors. MVA for the RENAL-NS subgroup was calculated without RENAL-NS as a covariate. Given the hypothesis-generating nature of these analyses, adjustment for multiple comparison was not performed. Though important to report results of these hypothesis-generating subgroup analyses to inform future research, these results should be interpreted with caution due to potential for spurious results.23

Statistical analyses were performed using SAS statistical software v9.4 (Cary, NC).

Results

Participant and Tumor Characteristics

Figure 1 shows the consort diagram for GRADE-SRM enrollment. Of 274 enrolled patients, 200 subjects completed both TP0 and TP1, 44 completed TP0 only and 6 completed TP1 only, for a total of 250 subjects available for analysis. Of these 250, 63 (25%) underwent RMB between TP0 and TP1. The mean age was 62.4 years (SD 11.3), 61% of patients were male, and 31% were non-white (Table 1). Mean renal mass diameter was 3.15 cm (SD 1.42) and mean RENAL-NS was 6.97 (SD 1.88) with 11% of masses having a high RENAL-NS.

Figure 1.

Figure 1.

Study enrollment and eligibility flowchart (CONSORT diagram).

aNot a renal mass (179), mass too large / advanced or possible metastatic disease (188), needed additional imaging (15), non-English speaking (34), possible metastatic lesion or history of metastatic cancer (6), prior knowledge or biopsy of SRM (274), incarcerated (11), possible recurrence disease (15), transplant patient (16)

bReason not indicated (reason not enrolled recorded starting 2/1/2019)

Table 1.

Patient characteristics and bivariable associations between patient characteristics and decision to undergo RMB. For categories without number missing indicated, no subjects were missing.

Covariate Level All patients (n = 250) RMB – No (n=187, 75%) RMB – Yes (n=63, 25%) PR (95% CI) P-value
Age (median (IQR)) 63.95 (54.55–70.00) 63.89 (53.23–70.00) 64.05 (59.29–70.24) 1.01 (0.99, 1.02) 0.46
Sex Female 99 (40%) 77 (78%) 22 (22%) 0.82 (0.52, 1.29) 0.37
Male 151 (60%) 110 (73%) 41 (27%) -
Ethnicity Non-hispanic White 170 (68%) 126 (74%) 44 (26%) - 0.71
All Other 80 (32%) 61 (76%) 19 (24%) 0.92 (0.57, 1.47)
Income < 50,000 115 (49%) 83 (72%) 32 (28%) - 0.76
50,000–99,999 66 (28%) 52 (79%) 14 (21%) 0.76 (0.44, 1.32)
100,000–149,999 24 (10%) 17 (71%) 7 (29%) 1.05 (0.53, 2.09)
150,000–199,999 17 (7%) 11 (65%) 6 (35%) 1.27 (0.62, 2.34)
> 200,000 13 (6%) 10 (77%) 3 (23%) 0.83 (0.29, 2.34)
Missing 15 14 1 -
Education High school or less 73 (30%) 57 (78%) 16 (22%) 0.71 (0.43, 1.17) 0.05
Some college / college graduate 136 (56%) 94 (69%) 42 (31%) -
Master’s or doctorate 36 (15%) 31 (86%) 5 (14%) 0.45 (0.19, 1.05)
Missing 5 5 0 -
Insurance type None 12 (5%) 8 (67%) 4 (33%) 1.12 (0.48, 2.62) 0.60
Private self-paid 9 (4%) 6 (67%) 3 (33%) 1.12 (0.42, 2.95)
Employer purchased 76 (30%) 61 (80%) 15 (20%) 0.66 (0.39, 1.14)
Medicare 104 (42%) 73 (70%) 31 (30%) -
Medicaid 19 (8%) 15 (79%) 4 (21%) 0.71 (0.28, 1.77)
Other / “I don’t know” / Missing 30 (12%) 24 (80%) 6 (20%) 0.67 (0.31, 1.46)
BMI (median (IQR)) 30.15 (26.70–35.80) 29.70 (26.30–35.50) 33.00 (28.50–37.80) 1.02 (1.00, 1.04) 0.14
Mass diameter 0–2 cm 64 (26%) 55 (86%) 9 (14%) - 0.02
2–4 cm 121 (48%) 89 (74%) 32 (26%) 1.88 (0.96, 3.69)
> 4 cm 65 (26%) 43 (66%) 22 (34%) 2.41 (1.20, 4.82)
Nephrome try score Low (4–6) 105 (43%) 86 (82%) 19 (18%) - 0.04
Moderate (7–9) 115 (47%) 81 (70%) 34 (30%) 1.63 (1.00, 2.68)
High (10–12) 26 (11%) 16 (61%) 10 (39%) 2.13 (1.13, 4.01)
Missing 4 4 0 -
Bilateral masses No 236 (84%) 178 (75%) 58 (25%) - 0.41
Yes 14 (6%) 9 (64%) 5 (36%) 1.45 (0.70, 3.04)
Mass type Solid 203 (81%) 149 (73%) 54 (27%) - 0.26
Cystic or mixed 47 (19%) 38 (81%) 9 (19%) 0.72 (0.38, 1.35)
ECOG Status 0 168 (67%) 129 (77%) 39 (23%) - 0.54
1 26 (10%) 20 (77%) 6 (23%) 0.99 (0.47, 2.11)
> 2 6 (2%) 3 (50%) 3 (50%) 2.15 (0.92, 5.02)
Missing 50 (20%) 35 (70%) 15 (30%) 1.29 (0.78, 2.14)
Smoking Status Current smoking 43 (17%) 38 (88%) 5 (12%) 0.41 (0.18, 0.97) 0.01
Former / Never Smoking or Unknown 207 (83%) 149 (72%) 58 (28%) -
Outside Urologist No 146 (58%) 112 (77%) 34 (23%) - 0.41
Yes 104 (42%) 75 (72%) 29 (28%) 1.20 (0.78, 1.83)
UNC Urologist 1 31 (12%) 27 (87%) 4 (13%) 0.41 (0.16, 1.06) 0.02
2 144 (58%) 99 (69%) 45 (31%) -
3 42 (17%) 37 (88%) 5 (12%) 0.38 (0.16, 0.90)
4 21 (8%) 15 (71%) 6 (29%) 0.91 (0.45, 1.88)
5/6^ 12 (5%) 9 (75%) 3 (25.0%) 0.80 (0.29, 2.20)
Comorbidity Index (median (IQR)) 4.00 (2.00–6.00) 4.00 (2.00–5.00) 4.00 (3.00–6.00) 1.03 (0.95, 1.12) 0.43
Maximizer – Minimizer (median (IQR)) 47.00 (40.00–52.00) 46.50 (39.00–52.00) 49.00 (41.00–53.00 1.02 (1.00, 1.05) 0.04
Missing: 37 9 -
Self-Efficacy (median (IQR)) 4.00 (3.50–4.50) 4.00 (3.50–4.75) 4.00 (3.50–4.50) 0.88 (0.63, 1.21) 0.42
Missing: 82 24 -
Patient Centered Communication (median (IQR)) 4.33 (3.83–4.67) 4.33 (3.82–4.67) 4.33 (4.00–4.60) 1.03 (0.72, 1.48) 0.85
Missing: 7 1 -
^

Combined two providers due to small numbers.

RMB was more prevalent for subjects with masses > 4 cm vs. 0–2 cm (PR 2.41, 95% CI 1.20–4.82, p = 0.01), and high RENAL-NS vs. low (PR 2.13, 95% CI 1.13–4.01, p=0.02) [Table 1]. RMB occurred less often for patients who smoke vs. did not (PR 0.41, 95% CI 0.18–0.97, p=0.04) and participants counseled by urologist 3 vs 2 (PR 0.38, 95% CI 0.16–0.90, p=0.03). Participants undergoing RMB had higher maximizer-minimizer scores (p=0.04).

Technical Outcomes of RMB

RMB diagnosed 21% with benign and 76% with malignant histology while 3.2% were non-diagnostic (Supplemental Table 1). Following RMB, 39 patients underwent surgical resection and, of diagnostic biopsies, there was a 95% concordance in benign versus malignant between RMB and surgical specimens. Of those with malignancy in the surgical specimen (N=36), there was 92% concordance in histologic subtype between RMB and surgical pathology. Complication from RMB occurred in 2 (3%) subjects (ED visit for pain, admission for retroperitoneal hematoma).

At TP1, subjects who underwent RMB elected surgery in 57% of cases, ablation in 14%, and AS in 25% (Supplemental Table 2). TP1 treatment distribution differed from patients who did not undergo RMB (p <0.001). Of patients who elected surgery at TP0 or TP1, 83% (88/106) of nephrectomy specimens demonstrated malignant pathology in those without RMB while 97% (34/35) were malignant in those who underwent RMB.

Impact of RMB on Decisional Conflict

Table 2 shows estimates from the unadjusted DiD model. Using all available data from the full 250 participants, estimated total DCS at TP0 was significantly higher for those who underwent RMB (20.1 vs. 16.1, p=0.03) but not at TP1 (19.2 vs. 18.1, p=0.60) (Figure 2). For participants reporting DCS scores at both timepoints (55 RMB vs 145 no RMB) the mean difference in change scores was not significant (−0.99 v 2.11, p=0.17 via t-test). Multivariable DiD for total DCS showed patients undergoing RMB had significantly higher DCS at TP0 compared to those who did not undergo RMB (4.84, p=0.01). There was not a significant difference in total DCS by RMB status at TP1 (2.07, p=0.38) and no significant DiD in total DCS (−2.77, p=0.20) by RMB status over time. Patient-level change in DCS varied (Figure 3A). Approximately 25% of participants in both groups reported an increase in total DCS between TP0 and TP1. However, a greater proportion in the RMB group experienced ≥0.5 standard deviation (7-point) decrease in total DCS compared to the no RMB group (36% vs. 15%, p=0.003, Figure 3B).

Table 2.

Unadjusted difference in difference results for DCS total.

DCS subdomain RMB status Estimated DCS at T0 (mean (stderr)) Diff at T0 (p-value) Estimated DCS at T1 (mean (stderr)) Diff at T1 (p-value) Change over time (mean, Std Error Change over time (p-value) Difference in change scores (stderr) Difference in change over time (p-value)
Total No 16.1 (1.08) 0.03 18.0 (1.26) 0.60 1.92 (1.15) 0.10 −2.78 (2.17) 0.20
Yes 20.1 (1.49) 19.2 (1.85) −0.86 (1.84) 0.64
Support No 12.4 (1.02) 0.04 13.6 (1.14) 0.24 1.17 (1.03) 0.25 −1.05 (1.91) 0.58
Yes 16.1 (1.49) 16.2 (1.89) 0.12 (1.61) 0.94
Decision-making No 15.4 (1.18) 0.04 16.5 (1.34) 0.90 1.10 (1.37) 0.42 −4.63 (2.82) 0.10
Yes 19.6 (1.72) 16.1 (2.31) −3.53 (2.46) 0.15
Uncertainty No 20.0 (1.45) 0.01 22.4 (1.79) 0.43 2.39 (1.71) 0.16 −4.58 (3.31) 0.17
Yes 27.1 (2.54) 24.9 (2.68) −2.19 (2.83) 0.44
Uninformed No 15.8 (1.19) 0.45 18.4 (1.47) 0.64 2.61 (1.32) 0.05 −0.20 (2.74) 0.94
Yes 17.2 (1.45) 19.7 (2.23) 2.42 (2.40) 0.31
Clarity of Values No 17.2 (1.19) 0.07 19.5 (1.44) 0.51 2.30 (1.39) 0.10 −2.06 (2.19) 0.35
Yes 20.7 (1.52) 21.0 (1.74) 0.24 (1.70) 0.89

Figure 2.

Figure 2.

Difference-in-difference analysis comparing total DCS at TP0 and TP1 by receipt of renal mass biopsy.

Figure 3.

Figure 3.

A. Change in total DCS between TP0 and TP1 by receipt of renal mass biopsy for those completing survey at both time points. Dotted line one-half standard deviation (7 points) of DCS total. B. Renal mass biopsy by one-half standard deviation change (7 points) in DCS total. Chi-square p-value = 0.003.

Impact of RMB on Secondary Outcomes

Participants undergoing RMB had significantly higher DCS subdomains of support, decision-making, and uncertainty at TP0 compared to those who did not undergo RMB (16.1 v 12.4, p = 0.04; 19.6 v 15.4, p = 0.04; 27.1 v 20.0, p = 0.01, respectively; Table 2). There were no significant differences in these subdomains at TP1. Though non-significant in MVA, DiD magnitudes were greater for the uncertainty and decision-making DCS subdomains (−4.66, p = 0.16; −4.94, p = 0.08, respectively). Anxiety, cancer worry, and patient centered communication scores did not differ by RMB (Supplemental Table 3).

Sensitivity and Subgroup Analyses

The primary findings did not differ substantially when limiting to those with clinical T1a renal masses, solid renal masses, or high DCS (Supplemental Table 4). For participants who did not see an outside urologist, DiD by RMB was large for total DCS (−6.22), ineffective decision-making (−7.52), and uncertainty (−10.1) (Supplemental Table 4). Additionally, DiD by RMB was large for ineffective decision-making for subjects with education more than high school (−6.81) and low self-efficacy (−10.8). The DiD by RMB was also large for uncertainty in both males (−8.38) and subjects reporting worse PCC (−16.9) (Supplemental Table 4). For subjects with lower information seeking behavior (API < 86), DiD by RMB was large for the uninformed DCS subdomain (10.1) and medium for the uncertainty subdomain (6.4).

Discussion

In this prospective clinical trial, RMB did not significantly decrease total decisional conflict in patients with cT1 renal masses. We noted greater use of RMB for participants with larger, more complex masses and those with higher healthcare seeking behavior. Aspects of the decision-making experience also appeared to improve for certain participants depending on education level, previous counseling, and communication quality.

Previous studies identified age, high BMI (> 25), higher CCI, solid lesion, juxta-hilar location, tumor size > 2.0 cm, high complexity tumors, and lower income as associated with a greater likelihood of undergoing RMB.24–26 In this study, high complexity RENAL-NS and larger masses were more likely to undergo biopsy, as well as participants who did not smoke. Lower use of biopsy in tumors < 2 cm may reflect technical feasibility and comfort in recommending AS for very small SRMs. Consistent with prior report, we also observed variability in RMB use among individual urologists.27

Despite evolution in SRM management, the role of RMB remains contested. Proponents argue RMB can avoid unnecessary surgery with decreased excision of benign tumors (3% vs 23%, p < 0.001).28 Opponents argue that RMB does not impact decision-making and patients are placed on AS despite data demonstrating low rates of AS nationally.29 The American Urological Association and American Society for Clinical Oncology recommend consideration of RMB when the result may alter management.3,4 In this study, we observed reduction in surgery for benign disease following RMB (3% vs. 17%) and treatment choice differed. Patients who underwent RMB were less likely to pursue AS, suggesting that confirmation of malignancy may prompt some patients to pursue treatment. However, a randomized controlled trial would be needed to clarify the causal relationship between RMB and treatment selection.

A less appreciated but equally important consideration is how RMB results impact patient decision-making. RMB provides a mechanism for improving patient-centered care by potentially reducing uncertainty and improving shared decision-making.30 In this study, patients who underwent RMB demonstrated a higher baseline total DCS compared to patients who did not. While DCS at TP1 decreased in patients who underwent RMB, total DCS increased over time in patients who did not, potentially demonstrating how patients progressively process information regarding new SRM diagnoses. This finding highlights the potential benefit of RMB on decision-making and is consistent with a previous study showing that most patients with SRMs would want to undergo a biopsy if offered.30

Furthermore, subgroup analyses highlight the potential for RMB to improve the decision-making process depending on counseling and patient capacity. Notably, patients who did not see a prior urologist demonstrated a significant association between RMB and DCS total and subdomains of decision-making and uncertainty. As above, urologist perspectives on RMB can differ greatly, and this finding may underscore the importance of consistent messaging across providers, as we hypothesize conflicting information about RMB may reduce its potential benefit on decision-making. Additionally, given the significant DiD by RMB in DCS seen among those with low education and low PCC scores, RMB may also offer a means to improve decision-making when patient-provider communication is suboptimal. Finally, subgroup analyses underscore the importance of individualizing counseling. Patients with lower self-efficacy experienced significant improvements in facets of their decision-making experience with RMB, while patients with lower information-seeking behavior experienced more difficulties in decision-making after gaining RMB information. Accordingly, RMB could find a role in supporting decision-making for certain patients depending on their predisposition. Further studies will evaluate patient subgroups in which RMB may improve or worsen DCS and the optimal communication framework to inform patients of this option.

Our findings should be considered in the context of limitations. First, this study is vulnerable to selection bias and confounding. Second, our results are subject to non-response bias since they are dependent on survey completion. However, dropout was similar by group (RMB 13% vs no RMB 19%). Third, as a single institutional study, it is subject to individual urologist and local practice patterns.

This study highlights the potential for RMB to improve the patient experience following SRM diagnosis through reduced decisional conflict for subsets of patients. Further evaluation of which patients may benefit from RMB and how we can improve communication may reduce decisional conflict and enable RMB to be a more effective decision-making tool. Additionally, the potential for prognostic information from genomic biomarkers performed on RMB tissue may improve RMB impact on the decision-making experience.

Conclusions:

RMB may modestly reduce decisional conflict in selected patients by offering greater diagnostic certainty. These results highlight the possible benefits of RMB in improving the patient experience and support its use in SRM evaluation. Future research will focus on which subgroups of patients benefit most and how RMB impacts treatment modality and PROs.

Supplementary Material

Supplemental Material
Protocol

Acknowledgements:

Funding:

This work was supported by the National Institutes of Health (UNC Integrated Translational Oncology Program T32-CA244125 to UNC/khg; UNC Oncology K12 2K12CA120780 to UNC/khg; National Center for Advancing Translational Sciences UL1TR002489 from the Clinical and Translational Science Award program) and UNC Lineberger Comprehensive Cancer Center UNCseq v2. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funder did not play a role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.

Footnotes

Conflicts of Interest:

Marc Bjurlin: Clinical investigator: Urogen, ImmunityBio, Janssen Research & Development, LLC, and Anchiano Therapeutics; Paid consultant: Urogen, IIntuitive; Advisory Board: Urogen, Imugene, Telix Pharmaceuticals

Kathryn Gessner: Research Funding: Bladder Cancer Advocacy Network, American Society of Clinical Oncology

William Kim: Consulting fees: Focal Medical, OncoRev, Janssen. Patents pending: BiG-BETS ICI response predictor. Stock: Abbvie, Amgen, Arvinas, BeiGene, Bristol Myers Squibb, Moderna, Natera, Revolution Medicines, Tango Therapeutics, Zentalis, Focal Medical. Research Funding: Merck.

Matthew I. Milowsky: Stock and Other Ownership Interests: Pfizer, Merck, Gilead Sciences; Research Funding: Merck (Inst), Genentech (Inst), Bristol Myers Squibb(Inst), Mirati Therapeutics (Inst), Seagen Inc (Inst), G1Therapeutics (Inst), Alliance Foundation Trials (Inst), Alliance for Clinical Trials in Oncology (Inst), Clovis Oncology (Inst), Arvinas (Inst), Regeneron (Inst), ALX Oncology (Inst), Hoosier Cancer Research Network (Inst), Novartis (Inst), Acrivon Therapeutic (Inst), Astellas Pharma (Inst), Accuray (Inst), PCCTC (Inst), OncoC4 (Inst), Flare Therapeutics (Inst), Loxo/Lilly (Inst), Roche (Inst); Other Relationship: Elsevier, Medscape, Research to Practice, Prime Education.

Matthew Nielsen: Relevant outside the work: Consultant: American Urological Association; Consultant: American College of Physicians; Grant funding: National Institutes of Health Mathew Raynor: Consultant, Intuitive Surgical.

Angela Smith: Research Funding from PCORI, AHRQ, Genentech, NIH, Merck-RTI, Urogen The remaining authors have no relevant conflicts of interest to disclose.

Data availability statement:

De-identified data are available upon request.

REFERENCES

  • 1.Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763 [DOI] [PubMed] [Google Scholar]
  • 2.Takagi T, Yoshida K, Wada A, et al. Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. Int J Clin Oncol. 2020;25(5):892–898. doi: 10.1007/s10147-020-01632-x [DOI] [PubMed] [Google Scholar]
  • 3.Finelli A, Ismaila N, Bro B, et al. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(6):668–680. doi: 10.1200/jco.2016.69.9645 [DOI] [PubMed] [Google Scholar]
  • 4.Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021;206(2):199–208. doi: 10.1097/ju.0000000000001911 [DOI] [PubMed] [Google Scholar]
  • 5.Feinberg A, Gessner KH, Deal AM, et al. Decisional Conflict Among Patients Newly Diagnosed With Clinical T1 Renal Masses: A Prospective Study. J Urol. 2024;212(2):320–330. doi: 10.1097/ju.0000000000004023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Parker PA, Alba F, Fellman B, et al. Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. Eur Urol. 2013;63(6):1122–1127. doi: 10.1016/j.eururo.2013.01.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ali SN, Tano Z, Landman J. The Changing Role of Renal Mass Biopsy. Urol Clin North Am. 2023;50(2):217–225. doi: 10.1016/j.ucl.2023.01.002 [DOI] [PubMed] [Google Scholar]
  • 8.Posielski NM, Bui A, Wells SA, et al. Risk Factors for Complications and Nondiagnostic Results following 1,155 Consecutive Percutaneous Core Renal Mass Biopsies. J Urology. 2019;201(6):1080–1087. doi: 10.1097/ju.0000000000000113 [DOI] [PubMed] [Google Scholar]
  • 9.Marconi L, Dabestani S, Lam TB, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol. 2016;69(4):660–673. doi: 10.1016/j.eururo.2015.07.072 [DOI] [PubMed] [Google Scholar]
  • 10.Breau RH, Crispen PL, Jenkins SM, Blute ML, Leibovich BC. Treatment of Patients With Small Renal Masses: A Survey of the American Urological Association. J Urol. 2011;185(2):407–414. doi: 10.1016/j.juro.2010.09.092 [DOI] [PubMed] [Google Scholar]
  • 11.Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Garvelink MM, Boland L, Klein K, et al. Decisional Conflict Scale Use over 20 Years: The Anniversary Review. Med Decis Making. 2018;39(4):301–314. doi: 10.1177/0272989×19851345 [DOI] [PubMed] [Google Scholar]
  • 13.Mouelhi Y, Jouve E, Castelli C, Gentile S. How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. Heal Qual Life Outcomes. 2020;18(1):136. doi: 10.1186/s12955-020-01344-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Dijkstra A, Brosschot J. Worry about health in smoking behaviour change. Behav Res Ther. 2003;41(9):1081–1092. doi: 10.1016/s0005-7967(02)00244-9 [DOI] [PubMed] [Google Scholar]
  • 15.Kroenke K, Yu Z, Wu J, Kean J, Monahan PO. PROMIS Four-Item Depression and Anxiety Scales. Pain Med. 2014;15(11):1892–1901. doi: 10.1111/pme.12537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.McCormack LA, Treiman K, Rupert D, et al. Measuring patient-centered communication in cancer care: A literature review and the development of a systematic approach. Soc Sci Med. 2011;72(7):1085–1095. doi: 10.1016/j.socscimed.2011.01.020 [DOI] [PubMed] [Google Scholar]
  • 17.Hew MN, Baseskioglu B, Barwari K, et al. Critical Appraisal of the PADUA Classification and Assessment of the R.E.N.A.L. Nephrometry Score in Patients Undergoing Partial Nephrectomy. J Urology. 2011;186(1):42–46. doi: 10.1016/j.juro.2011.03.020 [DOI] [PubMed] [Google Scholar]
  • 18.Scherer LD, Caverly TJ, Burke J, et al. Development of the Medical Maximizer-Minimizer Scale. Health Psychol. 2016;35(11):1276–1287. doi: 10.1037/hea0000417 [DOI] [PubMed] [Google Scholar]
  • 19.Salsman JM, Schalet BD, Merluzzi TV, et al. Calibration and initial validation of a general self-efficacy item bank and short form for the NIH PROMIS®. Qual Life Res. 2019;28(9):2513–2523. doi: 10.1007/s11136-019-02198-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ende J, Kazis L, Ash A, Moskowitz MA. Measuring patients’ desire for autonomy. J Gen Intern Med. 1989;4(1):23–30. doi: 10.1007/bf02596485 [DOI] [PubMed] [Google Scholar]
  • 21.Dimick JB, Ryan AM. Methods for Evaluating Changes in Health Care Policy: The Difference-in-Differences Approach. JAMA. 2014;312(22):2401–2402. doi: 10.1001/jama.2014.16153 [DOI] [PubMed] [Google Scholar]
  • 22.Pel-Littel RE, Buurman BM, Minkman MM, Reimer WJMS op, Twisk JWR, Weert JCM van. The influence of health literacy, anxiety and education on shared decision making and decisional conflict in older adults, and the mediating role of patient participation: A video observational study. Patient Educ Couns. 2024;124:108274. doi: 10.1016/j.pec.2024.108274 [DOI] [PubMed] [Google Scholar]
  • 23.Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G. How to Use a Subgroup Analysis: Users’ Guide to the Medical Literature. JAMA. 2014;311(4):405–411. doi: 10.1001/jama.2013.285063 [DOI] [PubMed] [Google Scholar]
  • 24.Patel AK, Lane BR, Chintalapati P, et al. Utilization of Renal Mass Biopsy for T1 Renal Lesions across Michigan: Results from MUSIC-KIDNEY, A Statewide Quality Improvement Collaborative. European Urology Open Sci. 2021;30:37–43. doi: 10.1016/j.euros.2021.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Tan HJ, Jacobs BL, Hafez KS, et al. Understanding the Role of Percutaneous Biopsy in the Management of Patients With a Small Renal Mass. Urology. 2012;79(2):372–377. doi: 10.1016/j.urology.2011.09.050 [DOI] [PubMed] [Google Scholar]
  • 26.Patel HD, Nichols PE, Su ZT, et al. Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer. Urology. 2020;135:76–81. doi: 10.1016/j.urology.2019.08.043 [DOI] [PubMed] [Google Scholar]
  • 27.Prebay ZJ, Patel A, Johnson A, et al. Perspectives on the Role of Biopsy for Management of T1 Renal Masses: Survey Results From Two Regional Quality Improvement Collaboratives. Urology. 2022;165:206–211. doi: 10.1016/j.urology.2022.01.038 [DOI] [PubMed] [Google Scholar]
  • 28.Okhunov Z, Gorin MA, Jefferson FA, et al. Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses? Urologic Oncol Seminars Orig Investigations. 2021;39(10):735.e17–735.e23. doi: 10.1016/j.urolonc.2021.05.024 [DOI] [PubMed] [Google Scholar]
  • 29.Nguyen KA, Nolte AC, Alimi O, et al. Determinants of Active Surveillance in Patients With Small Renal Masses. Urology. 2019;123:167–173. doi: 10.1016/j.urology.2018.07.021 [DOI] [PubMed] [Google Scholar]
  • 30.Chung R, Kurtzman JT, Gillespie A, et al. The Utility of Renal Mass Biopsy in Shared Decision Making for Renal Mass Treatment. Urology. Published online 2023. doi: 10.1016/j.urology.2023.04.023 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Material
Protocol

Data Availability Statement

De-identified data are available upon request.

RESOURCES